Skip to main content
European Commission logo print header
Content archived on 2022-12-23

Design, synthesis and evaluation of new antiviral and anticancer agents

Objective



The project will focus on the design and chemical synthesis of various new compounds (including 2',3'-dideoxynucleoside analogues, phosphonate derivatives thereof, acyclic nucleosides, anthracycline and streptonigrin derivatives, and quinoxalines), which will then be evaluated in Leuven for their antiviral and antitumor activity. A wide variety of viruses (including influenza and other respiratory viruses, herpes simplex virus, varicella-zoster virus, cytomegalovirus, human immunodeficiency virus and other retroviruses) and tumour such as leukemia, lymphoma, carcinoma, cell systems will be included in this project.

In addition, a series of mutant viruses and tumour cell lines, for which the mutations and/or enzyme defects are well-characterised, will be included in the evaluation of the novel compounds to allow more insight into the molecular interaction of the test compounds with their target enzymes (proteins) and/or the metabolic pathways involved to convert the test compounds to their metabolically active form.

The chemical part of the project will be carried out by the five NIS partners and in the U.K. the biological part will fall under the responsibility of th Leuven group.

Call for proposal

Data not available

Funding Scheme

Data not available

Coordinator

Katholieke Universiteit Leuven
EU contribution
No data
Address
Minderbroedersstraat 10
3000 Leuven
Belgium

See on map

Total cost
No data

Participants (5)